{
    "name": "smallpox (vaccinia) vaccine, live",
    "comment": "Rx",
    "other_names": [
        "ACAM2000"
    ],
    "classes": [
        "Vaccines",
        "Live",
        "Viral"
    ],
    "source": "https://reference.medscape.com/drug/acam2000-smallpox-vaccinia-vaccine-live-343270",
    "pregnancy": {
        "common": [
            "Pregnancy Category: D; has not been studied in pregnant women",
            "The only setting in which vaccination of pregnant women should be considered is when exposure to smallpox is considered likely",
            "Live vaccinia virus vaccines can cause fetal harm when administered to a pregnant woman; congenital infection, principally occurring during the first trimester, has been observed after vaccination with live vaccinia smallpox vaccines, although the risk may be low",
            "Generalized vaccinia of the fetus, early delivery of a stillborn infant, or a high risk of perinatal death has been reported",
            "If this vaccine is used during pregnancy, or if the vaccinee lives in the same household with or has close contact with a pregnant women, the vaccinee should be apprised of the potential hazard to the fetus"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Not known if excreted in breast milk, not recommended for nursing women in non-emergency situations",
            "Live vaccinia virus can be inadvertently transmitted from a lactating mother to her infant",
            "Infants are at high risk of developing serious complications from live vaccinia smallpox vaccination"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [
                "Suspected cases of myocarditis and/or pericarditis have been observed in healthy adult primary vaccinees",
                "Encephalitis, encephalomyelitis, encephalopathy, progressive vaccinia, generalized vaccinia, severe vaccinial skin infections, erythema multiforme major (including Stevens-Johnson syndrome), and eczema resulting in permanent sequelae or death, ocular complications, blindness, and fetal death have occurred following either primary vaccination or revaccination with smallpox vaccines",
                "This is a live vaccinia virus that can be transmitted to persons who have close contact with the recipient of the vaccine, and the risks in contacts are the same as those for the vaccinated patient",
                "The risk for experiencing serious vaccination complications must be weighed against the risks for experiencing a potentially fatal smallpox infection"
            ],
            "specific": [
                {
                    "type": "Risks increased with the following conditions",
                    "description": [
                        "These risks of severe adverse effects are increased with the following conditions and may result in severe disability, permanent neurologic sequelae, and/or death",
                        "Cardiac disease or a history of cardiac disease",
                        "Eye disease treated with topical steroids",
                        "Congenital or acquired immune deficiency disorders, including those taking immunosuppressive medications",
                        "Eczema and persons with a history of eczema or other acute or chronic exfoliative skin conditions",
                        "Infants aged <1 yr",
                        "Pregnancy"
                    ]
                }
            ]
        },
        "contraindicators": {
            "common": [
                "There are very few absolute contraindications to the vaccine for those who are at high risk for smallpox",
                "The risk for experiencing serious vaccination complications must be weighed against the risks for experiencing a potentially fatal smallpox infection; see Cautions for persons who are at higher risk of experiencing serious vaccination complications"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Serious complications may follow vaccination and may include myocarditis and/or pericarditis, encephalitis, encephalomyelitis, encephalopathy, progressive vaccinia (vaccinia necrosum), generalized vaccinia, severe vaccinial skin infections, erythema multiforme major (including Stevens-Johnson syndrome), eczema vaccinatum, blindness, and fetal death in pregnant women; these complications may rarely lead to severe disability, permanent neurological sequelae, and death",
                "Ischemic cardiac events and nonischemic, dilated cardiomyopathy have been reported following smallpox vaccination; relationship to the vaccine is unknown",
                "Accidental infection of the eye (ocular vaccinia) may result in ocular keratitis, corneal scarring, and blindness",
                "Severe localized or systemic infection with vaccinia (progressive vaccinia) may occur in persons with weakened immune systems, including those with leukemia, lymphoma, organ transplantation, generalized malignancy, HIV/AIDS, cellular or humoral immune deficiency, radiation therapy, or treatment with antimetabolites, alkylating agents, high-dose corticosteroids (>10 mg prednisone/day or equivalent for â‰¥2 weeks), or other immunomodulatory drugs; contraindicated in individuals with severe immunodeficiency (see Contraindications)",
                "Persons with eczema of any description such as, atopic dermatitis, neurodermatitis, and other eczematous conditions, regardless of severity of the condition, or persons who have a history of these conditions at any time in the past, are at higher risk of developing eczema vaccinatum",
                "Not studied in infants or children; risk of serious adverse events is higher in infants; vaccinated persons who have close contact with infants (eg, breastfeeding women), must take precautions to avoid inadvertent transmission of live vaccinia virus to infants",
                "Not studied in pregnant women; live vaccinia virus vaccines can cause fetal vaccinia and fetal death; if administered during pregnancy, the vaccinee should be apprised of the potential hazard to the fetus; pregnant women who are close contacts of vaccinees may be at increased risk because live vaccinia virus can shed and be transmitted to close contacts",
                "Contains neomycin and polymyxin B; caution with history of allergy to these components on",
                "Vaccinia immune globulin (VIG) is indicated for certain complications of vaccination live vaccinia virus smallpox vaccine; if VIG is needed or additional information is required, physicians should contact the CDC at (404) 639-3670 (M-F) or (404) 639-2888 evenings/weekends",
                "The most important measure to prevent inadvertent auto-inoculation and contact transmission from vaccinia vaccination is thorough hand washing after changing the bandage or after any other contact with the vaccination site",
                "Avoid blood and organ donation for at least 30 days following vaccination"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Contraindicated",
            "interaction_with": "belimumab",
            "description": {
                "common": "belimumab decreases effects of smallpox (vaccinia) vaccine, live by immunosuppressive effects; risk of infection. Contraindicated. Do not administer live vaccines 30 days before or concurrently with belimumab."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "certolizumab pegol",
            "description": {
                "common": "certolizumab pegol decreases effects of smallpox (vaccinia) vaccine, live by pharmacodynamic antagonism. Contraindicated. Do not give live vaccines concurrently with certolizumab."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "ibrutinib",
            "description": {
                "common": "ibrutinib decreases effects of smallpox (vaccinia) vaccine, live by pharmacodynamic antagonism. Contraindicated. Immunosuppressives may diminish therapeutic effects of vaccines and increase risk of adverse effects (increased risk of infection). Live-attenuated vaccines should be avoided for at least 3 mo after cessation of immunosuppressive therapy."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "ifosfamide",
            "description": {
                "common": "ifosfamide decreases effects of smallpox (vaccinia) vaccine, live by pharmacodynamic antagonism. Contraindicated. Immunosuppressives may diminish therapeutic effects of vaccines and increase risk of adverse effects (increased risk of infection). Live-attenuated vaccines should be avoided for at least 3 mo. after cessation of immunosuppressive therapy."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "ixekizumab",
            "description": {
                "common": "ixekizumab decreases effects of smallpox (vaccinia) vaccine, live by immunosuppressive effects; risk of infection. Contraindicated. Ixekizumab may interfere with immune response of live vaccines and increase risk for vaccine adverse effects; prior to initiating ixekizumab, complete all age appropriate immunizations."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "mechlorethamine",
            "description": {
                "common": "mechlorethamine decreases effects of smallpox (vaccinia) vaccine, live by immunosuppressive effects; risk of infection. Contraindicated. Immunosuppressives may diminish therapeutic effects of vaccines and increase risk of adverse effects (increased risk of infection). Live-attenuated vaccines should be avoided for at least 3 mo after cessation of immunosuppressive therapy."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "melphalan",
            "description": {
                "common": "melphalan decreases effects of smallpox (vaccinia) vaccine, live by pharmacodynamic antagonism. Contraindicated. Immunosuppressives may diminish therapeutic effects of vaccines and increase risk of adverse effects (increased risk of infection). Live-attenuated vaccines should be avoided for at least 3 mo. after cessation of immunosuppressive therapy."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "methotrexate",
            "description": {
                "common": "methotrexate decreases effects of smallpox (vaccinia) vaccine, live by pharmacodynamic antagonism. Contraindicated. Immunization with live virus vaccines is generally not recommended."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "onasemnogene abeparvovec",
            "description": {
                "common": "onasemnogene abeparvovec decreases effects of smallpox (vaccinia) vaccine, live by immunosuppressive effects; risk of infection. Contraindicated. Adjust vaccinations to accommodate concomitant corticosteroid administration prior to and following onasemnogene abeparvovec infusion. Avoid live vaccines for at least 1 month when initiating or after high-dose systemic corticosteroid therapy administered for =2 weeks."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "oxaliplatin",
            "description": {
                "common": "oxaliplatin decreases effects of smallpox (vaccinia) vaccine, live by pharmacodynamic antagonism. Contraindicated. Immunosuppressives may diminish therapeutic effects of vaccines and increase risk of adverse effects (increased risk of infection). Live-attenuated vaccines should be avoided for at least 3 mo. after cessation of immunosuppressive therapy."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "procarbazine",
            "description": {
                "common": "procarbazine decreases effects of smallpox (vaccinia) vaccine, live by pharmacodynamic antagonism. Contraindicated. Immunosuppressives may diminish therapeutic effects of vaccines and increase risk of adverse effects (increased risk of infection). Live-attenuated vaccines should be avoided for at least 3 mo after cessation of immunosuppressive therapy."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "secukinumab",
            "description": {
                "common": "secukinumab decreases effects of smallpox (vaccinia) vaccine, live by immunosuppressive effects; risk of infection. Contraindicated. Secukinumab may interfere with immune response of live vaccines and increase risk for vaccine adverse effects; prior to initiating secukinumab, complete all age appropriate immunizations."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "ustekinumab",
            "description": {
                "common": "ustekinumab decreases effects of smallpox (vaccinia) vaccine, live by Mechanism: pharmacodynamic antagonism. Contraindicated. Prior initiating therapy, patients should receive all  age-appropriate immunizations as recommended by current guidelines. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "abrocitinib",
            "description": {
                "common": "abrocitinib decreases effects of smallpox (vaccinia) vaccine, live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Administration of live vaccines is not recommended during abrocitinib treatment and immediately before or after treatment."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "adalimumab",
            "description": {
                "common": "adalimumab decreases effects of smallpox (vaccinia) vaccine, live by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "alefacept",
            "description": {
                "common": "alefacept decreases effects of smallpox (vaccinia) vaccine, live by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "anakinra",
            "description": {
                "common": "anakinra decreases effects of smallpox (vaccinia) vaccine, live by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "anifrolumab",
            "description": {
                "common": "anifrolumab decreases effects of smallpox (vaccinia) vaccine, live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Before initiation, update immunization according to current guidelines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "antithymocyte globulin equine",
            "description": {
                "common": "antithymocyte globulin equine decreases effects of smallpox (vaccinia) vaccine, live by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "antithymocyte globulin rabbit",
            "description": {
                "common": "antithymocyte globulin rabbit decreases effects of smallpox (vaccinia) vaccine, live by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "atoltivimab/maftivimab/odesivimab",
            "description": {
                "common": "atoltivimab/maftivimab/odesivimab decreases effects of smallpox (vaccinia) vaccine, live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Ebola monoclonal antibodies may interfere with immune response of live vaccines. Refer to vaccine guidelines for vaccination timing during and following treatment. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "axicabtagene ciloleucel",
            "description": {
                "common": "axicabtagene ciloleucel decreases effects of smallpox (vaccinia) vaccine, live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid live virus vaccines for at least 6 weeks before initiating lymphodepleting therapy, during axicabtagene ciloleucel treatment, and after treatment until full immune recovery is achieved."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "azathioprine",
            "description": {
                "common": "azathioprine decreases effects of smallpox (vaccinia) vaccine, live by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "baricitinib",
            "description": {
                "common": "baricitinib decreases effects of smallpox (vaccinia) vaccine, live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid use of live vaccines with baricitinib. Update immunizations in agreement with current immunization guidelines before initiating baricitinib."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "basiliximab",
            "description": {
                "common": "basiliximab decreases effects of smallpox (vaccinia) vaccine, live by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "brexucabtagene autoleucel",
            "description": {
                "common": "brexucabtagene autoleucel decreases effects of smallpox (vaccinia) vaccine, live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid live virus vaccines for at least 6 weeks before initiating lymphodepleting therapy, during brexucabtagene autoleucel treatment, and after treatment until full immune recovery is achieved."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "budesonide",
            "description": {
                "common": "budesonide decreases effects of smallpox (vaccinia) vaccine, live by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cabazitaxel",
            "description": {
                "common": "cabazitaxel decreases effects of smallpox (vaccinia) vaccine, live by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Live attenuated vaccines should not be used in patients receiving immunosuppressive therapy. Immunosuppressives may diminish therapeutic effects of vaccines and increase risk of adverse effects."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "canakinumab",
            "description": {
                "common": "canakinumab decreases effects of smallpox (vaccinia) vaccine, live by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ciltacabtagene autoleucel",
            "description": {
                "common": "ciltacabtagene autoleucel decreases effects of smallpox (vaccinia) vaccine, live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Vaccination with live virus vaccines is not recommended for at least 6 weeks before starting lymphodepleting chemotherapy, during CAR-T cell treatment, and until immune recovery following treatment. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cortisone",
            "description": {
                "common": "cortisone decreases effects of smallpox (vaccinia) vaccine, live by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cyclosporine",
            "description": {
                "common": "cyclosporine decreases effects of smallpox (vaccinia) vaccine, live by pharmacodynamic antagonism. Contraindicated. Avoid live vaccines in immunocompromised patients due to the risk of developing a clinical infection from the live vaccine. Inadequate immune response to the vaccine may also occur in the presence of immunosuppressants. Avoid live vaccines for at least 3 months after cessation of immunosuppressant therapy unless the benefit of vaccine administration outweighs the potential risk."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "deflazacort",
            "description": {
                "common": "deflazacort decreases effects of smallpox (vaccinia) vaccine, live by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dexamethasone",
            "description": {
                "common": "dexamethasone decreases effects of smallpox (vaccinia) vaccine, live by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dupilumab",
            "description": {
                "common": "dupilumab, smallpox (vaccinia) vaccine, live. immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Prior to initiating dupilumab, complete all age appropriate immunizations. Avoid use of live vaccines in patients treated with dupilumab."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "elivaldogene autotemcel",
            "description": {
                "common": "elivaldogene autotemcel, smallpox (vaccinia) vaccine, live.\nEither decreases effects of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: The safety and effectiveness of vaccination during or following elivaldogene autotemcel treatment have not been studied. Vaccination is not recommended during the 6 weeks preceding myeloablative conditioning, and until hematological recovery following elivaldogene autotemcel treatment. Where feasible, administer childhood vaccinations before myeloablative conditioning. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "etanercept",
            "description": {
                "common": "etanercept decreases effects of smallpox (vaccinia) vaccine, live by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "everolimus",
            "description": {
                "common": "everolimus decreases effects of smallpox (vaccinia) vaccine, live by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fingolimod",
            "description": {
                "common": "fingolimod decreases effects of smallpox (vaccinia) vaccine, live by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Avoid live attenuated vaccines during and for 2 months after stopping fingolimod."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fludrocortisone",
            "description": {
                "common": "fludrocortisone decreases effects of smallpox (vaccinia) vaccine, live by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "glatiramer",
            "description": {
                "common": "glatiramer decreases effects of smallpox (vaccinia) vaccine, live by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "golimumab",
            "description": {
                "common": "golimumab decreases effects of smallpox (vaccinia) vaccine, live by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "guselkumab",
            "description": {
                "common": "guselkumab, smallpox (vaccinia) vaccine, live. immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Prior to initiating guselkumab, complete all age appropriate immunizations. No data available on the ability of live or inactive vaccine to elicit an immune response in patients treated with guselkumab."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "hydrocortisone",
            "description": {
                "common": "hydrocortisone decreases effects of smallpox (vaccinia) vaccine, live by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "hydroxychloroquine sulfate",
            "description": {
                "common": "hydroxychloroquine sulfate decreases effects of smallpox (vaccinia) vaccine, live by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "hydroxyurea",
            "description": {
                "common": "hydroxyurea decreases effects of smallpox (vaccinia) vaccine, live by Other (see comment). Avoid or Use Alternate Drug. \nComment: Vaccination with live vaccines in a patient receiving hydroxyurea may diminish therapeutic effects of vaccines and increase risk of adverse effects (increased risk of infection)."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "idecabtagene vicleucel",
            "description": {
                "common": "idecabtagene vicleucel decreases effects of smallpox (vaccinia) vaccine, live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Vaccination with live virus vaccines is not recommended for at least 6 weeks before starting lymphodepleting chemotherapy, during CAR-T cell treatment, and until immune recovery following treatment. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "infliximab",
            "description": {
                "common": "infliximab decreases effects of smallpox (vaccinia) vaccine, live by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "leflunomide",
            "description": {
                "common": "leflunomide decreases effects of smallpox (vaccinia) vaccine, live by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lomustine",
            "description": {
                "common": "lomustine decreases effects of smallpox (vaccinia) vaccine, live by pharmacodynamic antagonism. Contraindicated. Immunosuppressives may diminish therapeutic effects of vaccines and increase risk of adverse effects (increased risk of infection). Live-attenuated vaccines should be avoided for at least 3mo after cessation of immunosuppressive therapy."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "mercaptopurine",
            "description": {
                "common": "mercaptopurine decreases effects of smallpox (vaccinia) vaccine, live by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "methylprednisolone",
            "description": {
                "common": "methylprednisolone decreases effects of smallpox (vaccinia) vaccine, live by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "muromonab CD3",
            "description": {
                "common": "muromonab CD3 decreases effects of smallpox (vaccinia) vaccine, live by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "mycophenolate",
            "description": {
                "common": "mycophenolate decreases effects of smallpox (vaccinia) vaccine, live by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ocrelizumab",
            "description": {
                "common": "ocrelizumab decreases effects of smallpox (vaccinia) vaccine, live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Vaccination with live-attenuated or live vaccines is not recommended during ocrelizumab treatment and until B-cell repletion."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ofatumumab SC",
            "description": {
                "common": "ofatumumab SC decreases effects of smallpox (vaccinia) vaccine, live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Administer all immunizations according to immunization guidelines at least 4 weeks prior to initiation of ofatumumab SC for live or live-attenuated vaccines, and whenever possible."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ozanimod",
            "description": {
                "common": "ozanimod decreases effects of smallpox (vaccinia) vaccine, live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid use of live-attenuated vaccines with ozanimod during treatment and for up to 3 months after discontinuing ozanimod. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ponesimod",
            "description": {
                "common": "ponesimod decreases effects of smallpox (vaccinia) vaccine, live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid use of live attenuated vaccines at least 1 month before initiating, during, and for 1-2 weeks after treatment. Coadministration with live attenuated vaccines may increase infection risk."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "prednisolone",
            "description": {
                "common": "prednisolone decreases effects of smallpox (vaccinia) vaccine, live by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "prednisone",
            "description": {
                "common": "prednisone decreases effects of smallpox (vaccinia) vaccine, live by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rilonacept",
            "description": {
                "common": "rilonacept decreases effects of smallpox (vaccinia) vaccine, live by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "risankizumab",
            "description": {
                "common": "risankizumab decreases effects of smallpox (vaccinia) vaccine, live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid use of live vaccines. Before starting risankizumab, complete age appropriate immunizations."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rituximab",
            "description": {
                "common": "rituximab, smallpox (vaccinia) vaccine, live. immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Safety of immunization with live viral vaccines following rituximab therapy has not been studied and vaccination with live virus vaccines is not recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rituximab-hyaluronidase",
            "description": {
                "common": "rituximab-hyaluronidase, smallpox (vaccinia) vaccine, live. immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Safety of immunization with live viral vaccines following rituximab therapy has not been studied and vaccination with live virus vaccines is not recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sarilumab",
            "description": {
                "common": "sarilumab, smallpox (vaccinia) vaccine, live. immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid concurrent use of live virus vaccines, owing to potentially increased risk of infections. The interval between live vaccinations and initiation of sarilumab therapy should be in accordance with current vaccination guidelines regarding immunosuppressive agents."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "satralizumab",
            "description": {
                "common": "satralizumab decreases effects of smallpox (vaccinia) vaccine, live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. ive vaccines are not recommended during treatment. Administer all immunizations according to immunization guidelines. At least 4 weeks before initiating for live or live-attenuated vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "siponimod",
            "description": {
                "common": "siponimod decreases effects of smallpox (vaccinia) vaccine, live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Pause vaccinations beginning 1 week before initiating siponimod and for 4 weeks after stopping treatment. Coadministration with live attenuated vaccines may increase infection risk."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sirolimus",
            "description": {
                "common": "sirolimus decreases effects of smallpox (vaccinia) vaccine, live by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tacrolimus",
            "description": {
                "common": "tacrolimus decreases effects of smallpox (vaccinia) vaccine, live by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "temsirolimus",
            "description": {
                "common": "temsirolimus decreases effects of smallpox (vaccinia) vaccine, live by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "teplizumab",
            "description": {
                "common": "teplizumab decreases effects of smallpox (vaccinia) vaccine, live by Other (see comment). Avoid or Use Alternate Drug. \nComment: Administer all age-appropriate vaccinations before starting teplizumab. Live-attenuated vaccines are not recommended within 8 weeks before teplizumab treatment, during treatment, or up to 52 weeks after treatment."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tildrakizumab",
            "description": {
                "common": "tildrakizumab decreases effects of smallpox (vaccinia) vaccine, live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Before initiating tildrakizumab therapy, consider completion of all age appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with tildrakizumab. No data are available on the response to live or inactive vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tisagenlecleucel",
            "description": {
                "common": "tisagenlecleucel decreases effects of smallpox (vaccinia) vaccine, live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Vaccination with live virus vaccines is not recommended for at least 6 weeks before starting lymphodepleting chemotherapy, during CAR-T cell treatment, and until immune recovery following treatment. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tocilizumab",
            "description": {
                "common": "tocilizumab decreases effects of smallpox (vaccinia) vaccine, live by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tralokinumab",
            "description": {
                "common": "tralokinumab decreases effects of smallpox (vaccinia) vaccine, live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid use of live vaccines. Before starting tralokinumab, complete age appropriate immunizations."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "triamcinolone acetonide injectable suspension",
            "description": {
                "common": "triamcinolone acetonide injectable suspension decreases effects of smallpox (vaccinia) vaccine, live by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "upadacitinib",
            "description": {
                "common": "upadacitinib decreases effects of smallpox (vaccinia) vaccine, live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ustekinumab",
            "description": {
                "common": "ustekinumab decreases effects of smallpox (vaccinia) vaccine, live by pharmacodynamic antagonism. Contraindicated. Prior initiating therapy, patients should receive all  age-appropriate immunizations as recommended by current guidelines. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "vedolizumab",
            "description": {
                "common": "vedolizumab decreases effects of smallpox (vaccinia) vaccine, live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid use of live virus vaccines while receiving vedolizumab; live vaccines may be administered concurrently with vedolizumab only if the benefits outweigh the risks."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "voclosporin",
            "description": {
                "common": "voclosporin decreases effects of smallpox (vaccinia) vaccine, live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Immunosuppressants also increase risk of infection with concomitant live vaccines. Avoid live vaccines for at least 3 months after immunosuppressants."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "anthrax immune globulin",
            "description": {
                "common": "anthrax immune globulin decreases effects of smallpox (vaccinia) vaccine, live by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Immune globulin administration may impair the efficacy of live attenuated vaccines. Defer vaccination with live virus vaccines until ~3 months after administration of anthrax IG. Revaccinate people who received anthrax IG shortly after live virus vaccination following 3 months after the administration of anthrax IG."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "belatacept",
            "description": {
                "common": "belatacept decreases effects of smallpox (vaccinia) vaccine, live by Other (see comment). Use Caution/Monitor. \nComment: The use of live vaccines should be avoided during treatment with belatacept. Inform patients that vaccinations may be less effective while they are being treated with belatacept."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "betibeglogene autotemcel",
            "description": {
                "common": "betibeglogene autotemcel, smallpox (vaccinia) vaccine, live. Other (see comment). Use Caution/Monitor. \nComment: Follow institutional guidelines for vaccine administration. Safety of live vaccines during or following treatment not studied. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cytomegalovirus immune globulin (CMV IG)",
            "description": {
                "common": "cytomegalovirus immune globulin (CMV IG) decreases effects of smallpox (vaccinia) vaccine, live by pharmacodynamic antagonism. Use Caution/Monitor. Separate by 3 months."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hepatitis B immune globulin (HBIG)",
            "description": {
                "common": "hepatitis B immune globulin (HBIG) decreases effects of smallpox (vaccinia) vaccine, live by pharmacodynamic antagonism. Use Caution/Monitor. Separate by 3 months."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "immune globulin IM (IGIM)",
            "description": {
                "common": "immune globulin IM (IGIM) decreases effects of smallpox (vaccinia) vaccine, live by pharmacodynamic antagonism. Use Caution/Monitor. Separate by 3 months."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "immune globulin IV (IGIV)",
            "description": {
                "common": "immune globulin IV (IGIV) decreases effects of smallpox (vaccinia) vaccine, live by pharmacodynamic antagonism. Use Caution/Monitor. Separate by 3 months."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "immune globulin SC",
            "description": {
                "common": "immune globulin SC decreases effects of smallpox (vaccinia) vaccine, live by pharmacodynamic antagonism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "leniolisib",
            "description": {
                "common": "leniolisib decreases effects of smallpox (vaccinia) vaccine, live by immunosuppressive effects; risk of infection. Use Caution/Monitor. Live, attenuated vaccinations may be less effective if administered during leniolisib treatment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "obinutuzumab",
            "description": {
                "common": "obinutuzumab decreases effects of smallpox (vaccinia) vaccine, live by immunosuppressive effects; risk of infection. Use Caution/Monitor. Immunization with live virus vaccines is not recommended during obinutuzumab treatment and until after B-cell recovery."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rabies immune globulin, human (RIG)",
            "description": {
                "common": "rabies immune globulin, human (RIG) decreases effects of smallpox (vaccinia) vaccine, live by Other (see comment). Use Caution/Monitor. \nComment: High dose rabies immunoglobulin may impair response to active immunization."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tecovirimat",
            "description": {
                "common": "tecovirimat, smallpox (vaccinia) vaccine, live. Other (see comment). Use Caution/Monitor. \nComment: No vaccine-drug interaction studies have been performed in humans. Some animal studies suggest a reduced immune response to smallpox vaccine if coadministered with tecovirimat. The clinical impact of this interaction on vaccine efficacy is unknown."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tetanus immune globulin (TIG)",
            "description": {
                "common": "tetanus immune globulin (TIG) decreases effects of smallpox (vaccinia) vaccine, live by pharmacodynamic antagonism. Use Caution/Monitor. Separate by 3 months."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ublituximab",
            "description": {
                "common": "ublituximab decreases effects of smallpox (vaccinia) vaccine, live by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Administer all immunizations according to immunization guidelines at least 4 weeks before initiating ublituximab for live or live-attenuated vaccines and, whenever possible, at least 2 weeks before initiating for non-live vaccines. Vaccination with live virus vaccines is not recommended during treatment and until B-cell repletion. Do not administer live or live-attenuated vaccines to infants of mothers exposed to ublituximab during pregnancy, before confirming recovery of B-cell counts as measured by CD19+ B cells."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "vaccinia immune globulin intravenous",
            "description": {
                "common": "vaccinia immune globulin intravenous decreases effects of smallpox (vaccinia) vaccine, live by pharmacodynamic antagonism. Use Caution/Monitor. Defer live vaccines for 3 months after immune globulin administration."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "chloroquine",
            "description": {
                "common": "chloroquine decreases effects of smallpox (vaccinia) vaccine, live by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "Rho(D) immune globulin",
            "description": {
                "common": "Rho(D) immune globulin decreases effects of smallpox (vaccinia) vaccine, live by pharmacodynamic antagonism. Minor/Significance Unknown. Separate by 3 months."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Injection site pruritus",
            "percent": "82-92"
        },
        {
            "name": "Injection site erythema",
            "percent": "61-74"
        },
        {
            "name": "Injection site pain",
            "percent": "37-67"
        },
        {
            "name": "Blood and lymphatic system disorders",
            "percent": "22-59"
        },
        {
            "name": "Lymph node pain",
            "percent": "19-57"
        },
        {
            "name": "Headache",
            "percent": "32-50"
        },
        {
            "name": "Injection site swelling",
            "percent": "28-48"
        },
        {
            "name": "Fatigue",
            "percent": "34-48"
        },
        {
            "name": "Myalgia",
            "percent": "27-46"
        },
        {
            "name": "Malaise",
            "percent": "28-37"
        },
        {
            "name": "Feeling hot",
            "percent": "20-32"
        },
        {
            "name": "GI disorders",
            "percent": "23-31"
        },
        {
            "name": "Erythema",
            "percent": "22-24"
        },
        {
            "name": "Rigors",
            "percent": "12-21"
        },
        {
            "name": "Nausea",
            "percent": "10-19"
        },
        {
            "name": "Diarrhea",
            "percent": "12-16"
        },
        {
            "name": "Decreased exercise tolerance",
            "percent": "8-11"
        },
        {
            "name": "Rash",
            "percent": "6-11"
        },
        {
            "name": "Constipation",
            "percent": "6"
        },
        {
            "name": "Vomiting",
            "percent": "3-5"
        },
        {
            "name": "Dyspnea",
            "percent": "3-4"
        },
        {
            "name": "Lymphadenopathy",
            "percent": "6-8"
        }
    ]
}